Search results for: Noriyuki Katsumata

Items from 1 to 20 out of 83 results

article

Prognostic Role of Tumor‐Infiltrating Lymphocytes and Tumor Budding in Early Oral Tongue Carcinoma

Yukiko Hori, Akira Kubota, Tomoyuki Yokose, Madoka Furukawa, more

The Laryngoscope > 131 > 11 > 2512 - 2518

Objectives/Hypothesis Occult lymph metastasis is an important prognosticator for the treatment of early oral tongue squamous cell carcinoma (SCC). The objective of this study was to evaluate the prognostic significance of tumor‐infiltrating lymphocytes (TILs) in early oral tongue SCC. The combination of the TIL subtype and intermediate‐ or high‐grade budding scores was investigated as a prognostic...

article

Japanese Dermatological Association Guidelines: Outlines of Guidelines for Cutaneous Squamous Cell Carcinoma 2020

Shin‐ichi Ansai, Yoshihiro Umebayashi, Noriyuki Katsumata, Hiroshi Kato, more

The Journal of Dermatology > 48 > 7 > e288 - e311

In consideration of the development of treatment options for squamous cell carcinoma (SCC), the Japanese Skin Cancer Society issued the first guidelines of SCC in 2007 and revised them in 2015. Here, we report the English version of the 2020 edition of the Japanese SCC guidelines. The first half of this article is an overview of SCC including actinic keratosis and Bowen’s disease, and the second half...

article

The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study

Kenichi Harano, Kan Yonemori, Akihiro Hirakawa, Chikako Shimizu, more

Breast Cancer > 2016 > 23 > 5 > 797-806

Background The social or familial factors influencing the location chosen for end-of-life (EOL) care for terminally ill breast cancer patients are unknown. Methods We retrospectively analyzed 195 patients with recurrent or progressive breast cancer who received anticancer treatment at the National Cancer Center Hospital between January 2008 and May 2012. Detailed data concerning the patients’ demographic,...

article

Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)

Koji Matsumoto, Noriyuki Katsumata, Taro Shibata, Toyomi Satoh, more

Gynecologic Oncology > 2015 > 136 > 2 > 218-223

To assess the safety and efficacy of the combination of oral etoposide and intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer.Eligible patients (age, 20–75years; platinum-free interval, ≤28weeks) with an adequate organ function received oral etoposide (50mg/m ² once a day) from day 1 to day 21 and intravenous irinotecan (70mg/m ² ) on days...

article

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

Yasutsuna Sasaki, Keisuke Miwa, Keishi Yamashita, Yu Sunakawa, more

Investigational New Drugs > 2015 > 33 > 2 > 332-340

Summary Farletuzumab is a humanized monoclonal antibody against folate receptor α (FRA). The purpose of the study is to assess safety and tolerability, the pharmacokinetic (PK) profile, and preliminary antitumor effect. Patients with ovarian cancer (OC) or FRA-expressing solid tumors who are resistant to standard treatments were eligible for the study. After single-dose administration for...

article

Dose-Dense Approaches to Ovarian Cancer Treatment

Noriyuki Katsumata

Current Treatment Options in Oncology > 2015 > 16 > 5 > 1-5

Opinion statement Currently, paclitaxel and carboplatin are administered every 3 weeks as the standard agents for the first-line treatment of advanced ovarian cancer. The concept of “dose-dense therapy” is based on the Norton-Simon hypothesis that a shorter interval between the doses of cytotoxic agents is more effective in reducing tumor burden than dose escalation. The results of phase...

article

Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey

Hitomi Sakai, Noriyuki Katsumata, Genmu Kadokura

BMC Cancer > 2015 > 15 > 1 > 1-8

Background This analysis was undertaken to evaluate the practice patterns of Japanese physicians regarding curative-intent chemotherapy, especially in outpatient settings, and to define factors negatively affecting the maintenance of relative dose intensity (RDI). Methods We performed a web-based questionnaire survey of Japanese physicians involved in malignant lymphoma chemotherapy (Group ML) or...

article

Two novel HSD3B2 missense mutations with diverse residual enzymatic activities for Δ5‐steroids

Kei Takasawa, Makoto Ono, Atsushi Hijikata, Yohei Matsubara, more

Clinical Endocrinology > 80 > 6 > 782 - 789

ContextClassical 3β‐hydroxysteroid dehydrogenase (3β‐HSD) deficiency (3β‐HSDD) is caused by loss‐of‐function mutations in the HSD3B2 gene encoding type II 3β‐HSD, which has a key role in steroid biosynthesis, converting Δ5‐steroids to Δ4‐steroids in adrenal glands and gonads. PatientA patient (46, XX) was found to have elevated 17‐hydroxyprogesterone (17‐OHP) [203 nmol/l (normal range: 2·94 ± 0·9 nmol/l)]...

article

Questionnaire-based survey on chemotherapy-induced anemia

Asashi Tanaka, Ichiro Yoshino, Shigeyoshi Makino, Noriyuki Katsumata, more

International Journal of Clinical Oncology > 2014 > 19 > 3 > 411-420

A questionnaire-based survey on chemotherapy-induced anemia (CIA) in cancer patients was conducted between September and November 2010. The number of patients treated with chemotherapy, rate of blood transfusion, volume of blood transfused, severity of anemia, and factors affecting blood transfusion were analyzed according to the type of cancer, in an attempt to clarify the current status of CIA in...

article

Dose-dense effect: other contributors – Author's reply

Noriyuki Katsumata

The Lancet Oncology > 2013 > 14 > 12 > e489-e490

article

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi, Fumiaki Takahashi, more

The Lancet Oncology > 2013 > 14 > 10 > 1020-1026

The primary analysis of the JGOG 3016 trial showed that a dose-dense paclitaxel and carboplatin regimen significantly improves progression-free and overall survival compared with the conventional regimen as first-line chemotherapy for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. We report the long-term follow-up results for survival. This randomised controlled...

article

Triple a syndrome in Japan

Masanori Ikeda, Makito Hirano, Keiich Shinoda, Noriyuki Katsumata, more

Muscle & Nerve > 48 > 3 > 381 - 386

IntroductionTriple A syndrome is an autosomal recessive disease, characterized by esophageal achalasia, alacrima, and adrenal insufficiency, as well as involvement of the central, peripheral, and autonomic nervous systems. This disease mimics amyotrophic lateral sclerosis in some patients. The causative gene encodes ALADIN, a nuclear pore complex (NPC) component. Only 5 patients have been reported...

article

Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: Individual patient data from Japanese randomized, placebo‐controlled trials

Yasuo Ohashi, Yukari Uemura, Yasuhito Fujisaka, Toru Sugiyama, more

Cancer Science > 104 > 4 > 481 - 485

Erythropoiesis‐stimulating agents (ESA) reduce the need for transfusions and improve the quality of life in patients receiving chemotherapy, but several clinical trials have suggested that ESA might have a negative impact on survival. To evaluate the efficacy and safety of ESA, epoetin beta and darbepoetin alfa, including their impact on overall survival and thromboembolic events, we conducted an...

article

Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

Yuko Tanabe, Kenji Hashimoto, Chikako Shimizu, Akihiro Hirakawa, more

International Journal of Clinical Oncology > 2013 > 18 > 1 > 132-138

Background The long-term outcomes and risk factors of paclitaxel-induced peripheral neuropathy (PIPN) have not yet been fully elucidated. Methods We identified 219 breast cancer patients who received paclitaxel as adjuvant chemotherapy between 2002 and 2009. We retrospectively analyzed the incidence, time to onset, duration, and risk factors for PIPN by chart review. Results Of the 219 patients,...

article

A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer

Mayu Yunokawa, Noriyuki Katsumata, Harukaze Yamamoto, Makoto Kodaira, more

Cancer Chemotherapy and Pharmacology > 2013 > 71 > 5 > 1369-1374

Purpose To evaluate the feasibility of a cisplatin and S-1 combination regimen for the treatment for metastatic and recurrent cervical cancers, we performed this study prior to a randomized phase III trial to evaluate the clinical benefits of a cisplatin and S-1 combination regimen compared with cisplatin alone. Methods Cisplatin (50 mg/m², intravenously on day 1) and S-1 (80–120 mg/m², orally twice...

article

A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

Ryo Kitagawa, Noriyuki Katsumata, Masashi Ando, Chikako Shimizu, more

Gynecologic Oncology > 2012 > 125 > 2 > 307-311

The aim of this prospective trial was to evaluate the efficacy and safety of the combination of paclitaxel and carboplatin (TC) in patients with metastatic or recurrent cervical cancer.This was a multicenter phase II trial of 3 weekly paclitaxel 175mg/m ² 3-hour iv day 1 followed by carboplatin AUC5 1-hour iv day 1 for maximum of 6cycles until disease progression or prohibitive toxicity. Eligible...

article

The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors

Kenji Hashimoto, Hiroyuki Fujimoto, Tsutomu Kouno, Masahiro Koseki, more

Urologic Oncology: Seminars and Original Investigations > 2012 > 30 > 3 > 319-324

The optimal management of extragonadal germ cell tumor (EGGCT) and metachronous testicular germ cell tumor (MTGCT) has not been determined. Fifty-one consecutive patients with EGGCT were identified. Testicular palpation or ultrasonography to rule out a primary testicular tumor was performed. Pretreatment testicular biopsies were not performed. The incidence and outcome of MTGCT, and the prognosis...

article

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

Kojiro Shimozuma, Yasuo Ohashi, Ayano Takeuchi, Toshihiko Aranishi, more

Supportive Care in Cancer > 2012 > 20 > 12 > 3355-3364

Purpose To elucidate whether adjuvant taxane monotherapy is a feasible and tolerable for postoperative breast cancer patients, we evaluated the severity of chemotherapy-induced peripheral neuropathy (CIPN) and the relative tolerability of regimens by health-related quality of life (HRQOL) assessment in node-positive breast cancer patients treated with taxane-containing regimens. Methods We evaluated...

article

Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer

Masashi Ando, Kan Yonemori, Noriyuki Katsumata, Chikako Shimizu, more

Cancer Chemotherapy and Pharmacology > 2012 > 69 > 2 > 457-465

Purpose We conducted phase I and tolerability studies to determine the maximum tolerated dose (MTD) and recommended dose of nab-paclitaxel when administered weekly with solid tumors and to evaluate the tolerability of weekly administration at a dose of 150 mg/m² with metastatic breast cancer (MBC) as a first-line therapy in Japanese patients. Methods In this phase I study, patients with advanced...

article

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

Makiko Ono, Hitoshi Tsuda, Chikako Shimizu, Sohei Yamamoto, more

Breast Cancer Research and Treatment > 2012 > 132 > 3 > 793-805

The purpose of the present study was to identify histological surrogate predictive markers of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC). Among 474 patients who received NAC and subsequent surgical therapy for stage II–III invasive breast carcinoma between 1999 and 2007, 102 (22%) had TNBC, and 92 core needle biopsy (CNB) specimens...

Publication date

Set your own date range

INFONA - science communication portal

Search results for: Noriyuki Katsumata

Prognostic Role of Tumor‐Infiltrating Lymphocytes and Tumor Budding in Early Oral Tongue Carcinoma

Japanese Dermatological Association Guidelines: Outlines of Guidelines for Cutaneous Squamous Cell Carcinoma 2020

The influence of familial factors on the choice of the place of death for terminally ill breast cancer patients: a retrospective single-center study

Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

Dose-Dense Approaches to Ovarian Cancer Treatment

Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey

Two novel HSD3B2 missense mutations with diverse residual enzymatic activities for Δ5‐steroids

Questionnaire-based survey on chemotherapy-induced anemia

Dose-dense effect: other contributors – Author's reply

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

Triple a syndrome in Japan

Meta‐analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy‐induced anemia and mortality: Individual patient data from Japanese randomized, placebo‐controlled trials

Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer

A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer

The incidence and management of metachronous testicular germ cell tumors in patients with extragonadal germ cell tumors

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

Filter options

Publication date

Content availability

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Noriyuki Katsumata

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options